Estonia - Kiestonia - Ravimiamet

chanelle pharmaceuticals manufacturing limited - fiproniil - täpilahus - 134mg 1.34ml 1.34ml 18tk; 134mg 1.34ml 1.34ml 90tk; 134mg 1.34ml 1.34ml 9tk; 134mg 1.34ml 1.34ml 3tk; 134mg 1.34ml 1.34ml 150tk; 134mg 1.34ml 1.34ml 30tk; 134mg 1.34ml 1.34ml 1tk; 134mg 1.34ml 1.34ml 10tk; 134mg 1.34ml 1.34ml 8tk; 134mg 1.34ml 1.34ml 6tk; 134mg 1.34ml 1.34ml 4tk; 134mg 1.34ml 1.34ml 20tk; 134mg 1.34ml 1.34ml 12tk; 134mg 1.34ml 1.34ml 15tk

Estonia - Kiestonia - Ravimiamet

chanelle pharmaceuticals manufacturing limited - fiproniil - täpilahus - 134mg 1.34ml 1.34ml 60tk; 134mg 1.34ml 1.34ml 20tk; 134mg 1.34ml 1.34ml 90tk; 134mg 1.34ml 1.34ml 12tk; 134mg 1.34ml 1.34ml 4tk; 134mg 1.34ml 1.34ml 30tk; 134mg 1.34ml 1.34ml 2tk; 134mg 1.34ml 1.34ml 6tk; 134mg 1.34ml 1.34ml 3tk; 134mg 1.34ml 1.34ml 10tk; 134mg 1.34ml 1.34ml 1tk; 134mg 1.34ml 1.34ml 9tk; 134mg 1.34ml 1.34ml 8tk

Estonia - Kiestonia - Ravimiamet

chanelle pharmaceuticals manufacturing limited - fiproniil - täpilahus - 268mg 2.68ml 2.68ml 12tk; 268mg 2.68ml 2.68ml 21tk; 268mg 2.68ml 2.68ml 30tk; 268mg 2.68ml 2.68ml 3tk; 268mg 2.68ml 2.68ml 90tk; 268mg 2.68ml 2.68ml 4tk; 268mg 2.68ml 2.68ml 15tk; 268mg 2.68ml 2.68ml 24tk; 268mg 2.68ml 2.68ml 2tk; 268mg 2.68ml 2.68ml 150tk; 268mg 2.68ml 2.68ml 20tk; 268mg 2.68ml 2.68ml 8tk; 268mg 2.68ml 2.68ml 1tk

Estonia - Kiestonia - Ravimiamet

chanelle pharmaceuticals manufacturing limited - fiproniil - täpilahus - 67mg 0.67ml 0.67ml 12tk; 67mg 0.67ml 0.67ml 10tk; 67mg 0.67ml 0.67ml 15tk; 67mg 0.67ml 0.67ml 1tk; 67mg 0.67ml 0.67ml 30tk; 67mg 0.67ml 0.67ml 90tk; 67mg 0.67ml 0.67ml 3tk; 67mg 0.67ml 0.67ml 20tk; 67mg 0.67ml 0.67ml 4tk; 67mg 0.67ml 0.67ml 6tk

Estonia - Kiestonia - Ravimiamet

chanelle pharmaceuticals manufacturing limited - klindamütsiin - tablett - 25mg 100tk

Estonia - Kiestonia - Ravimiamet

chanelle pharmaceuticals manufacturing limited - ivermektiin+klorsuloon - süstelahus - 10mg+100mg 1ml 500ml 1tk; 10mg+100mg 1ml 250ml 1tk

Umoja wa Ulaya - Kiestonia - EMA (European Medicines Agency)

smithkline beecham plc - rosiglitazone, metformiin vesinikkloriid - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - avandamet on näidustatud ravi 2. tüüpi suhkurtõve patsientidel, eriti ülekaalulistel patsientidel:kellel ei ole võimalik saavutada piisavat glycaemic kontrolli nende maksimaalne talutav annus suuline metformiin üksi. triple suukaudne ravi sulphonylurea patsientidel, kellel on ebapiisav glycaemic kontrolli hoolimata dual suukaudne ravi nende maksimaalne talutav annus metformiin ja sulphonylurea (vt lõik 4.

Umoja wa Ulaya - Kiestonia - EMA (European Medicines Agency)

smithkline beecham plc - rosiglitasoon - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - rosiglitazone on näidustatud ravi 2. tüüpi suhkurtõve:kui monotherapy-patsientidel (eelkõige ülekaalulistel patsientidel) ebapiisavalt kontrollitud toitumise ja treeningu kohta, kellele metformiin ei sobi, sest vastunäidustused või intoleranceas dual suukaudne ravi kombinatsioonis-metformiin, patsientidel (eriti ülekaalulistel patsientidel), millel piisavalt glycaemic kontrolli hoolimata maksimaalne talutav annus monotherapy koos metformiin-sulphonylurea, ainult patsientidel, kes näitavad, sallimatuse, et metformiin või kellele metformiin on vastunäidustatud, ebapiisav glycaemic kontrolli hoolimata monotherapy koos sulphonylureaas kolmekordse suukaudse ravi kombinatsioonis-metformiin ja sulphonylurea, patsientidel (eriti ülekaalulistel patsientidel), millel piisavalt glycaemic kontrolli hoolimata dual suukaudne ravi (vt lõik 4.

Umoja wa Ulaya - Kiestonia - EMA (European Medicines Agency)

smithkline beecham ltd - rosiglitazone, glimepiride - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - avaglim on näidustatud ravi 2. tüüpi suhkurtõve patsientidele, kes ei suuda saavutada piisavat glycaemic kontrolli optimaalne annus sulphonylurea monotherapy, ning kellele metformiin ei sobi, sest vastunäidustus või sallimatuse.

Umoja wa Ulaya - Kiestonia - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; mesothelioma; colorectal neoplasms - antineoplastilised ained - melanomaopdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. relative to nivolumab monotherapy, an increase in progression free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression. adjuvant treatment of melanomaopdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. non-small cell lung cancer (nsclc)opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. malignant pleural mesothelioma (mpm)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. renal cell carcinoma (rcc)opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor risk advanced renal cell carcinoma. opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. classical hodgkin lymphoma (chl)opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant (asct) and treatment with brentuximab vedotin. squamous cell cancer of the head and neck (scchn)opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy. urothelial carcinomaopdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy. adjuvant treatment of urothelial carcinomaopdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of miuc. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy. oesophageal squamous cell carcinoma (oscc)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (oc or gejc)opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. gastric, gastro‑oesophageal junction (gej) or oesophageal adenocarcinomaopdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with her2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) ≥ 5.